Class · Senolytics · Emerging Longevity

Senolytics: Clearing Zombie Cells

Senolytics selectively kill senescent cells — the damaged cells that refuse to die, secrete inflammatory signals, and drive age-related decline. D+Q is the flagship; fisetin is the OTC cousin.

🔬 Senolytics are HighPeptides' bet on the clearest mechanistic pathway from lab longevity to clinical longevity — if it works in humans, it's the first real rejuvenation drug class.
0
Hit-and-Run Cycle
0
Between Cycles
0
Mouse Lifespan Extension

How It Works

🧟
Zombie Cell Clearance

Senescent cells accumulate with age — they refuse to divide but also refuse to die, secreting SASP cytokines that inflame surrounding tissue. Senolytics selectively trigger their apoptosis.

⚔️
BCL-2 Pathway Disruption

Dasatinib and quercetin disrupt the survival-protein signaling that senescent cells depend on. Healthy cells have alternate pathways; senescent cells don't.

🧠
Tissue-Wide Effects

In mice, D+Q cleared senescent cells across multiple organs: adipose, liver, kidney, lung, and brain. Functional outcomes improved in each.

🔬
Human Trials Underway

Small Phase 2 studies at Mayo Clinic and Baptist Health showing senescent-cell reduction in human fat tissue. Efficacy endpoints (frailty, IPF) still being collected.

What the Data Shows

Mouse healthspan extension (D+Q)
Mayo Clinic 2018
+36%
Mouse lifespan extension (naturally aged)
D+Q intermittent dosing
+10%
Adipose senescent-cell reduction (humans)
Open-label pilot
~30%
Definitive human efficacy RCT
Not yet reported
Pending

Key Takeaways

✅ What We Know
  • Senescent cell accumulation is a validated aging mechanism ("hallmark of aging")
  • D+Q reduces senescent cells in human adipose tissue (Mayo open-label data)
  • Mouse studies show healthspan + lifespan extension with intermittent dosing
  • Hit-and-run protocol is plausible — you don't need chronic exposure
  • Fisetin offers an OTC alternative with some of the same mechanism at lower potency
⚠️ What We Don't Know
  • Human efficacy for disease endpoints (frailty, fibrosis, cognition) is unproven
  • Dasatinib is a leukemia drug with known side effects (bleeding, edema, pleural effusion)
  • Optimal human dosing and cycling frequency not established
  • Senolytics may not clear ALL senescent cell subtypes
  • Rebound senescence — cells may re-accumulate between cycles

Frequently Asked Questions

What is the D+Q protocol?

Most protocols use dasatinib 100mg + quercetin 1000mg orally for 2 consecutive days, once per month. This matches the Mayo Clinic Phase 2 dosing and allows time for senescent cells to clear without chronic exposure to the drugs.

Can I do senolytics without a prescription?

Yes — fisetin alone is OTC and has senolytic activity at 20mg/kg doses. D+Q requires a prescription for dasatinib. Some anti-aging clinics prescribe D+Q specifically for senolytic use.

How often should I cycle senolytics?

Most protocols cycle monthly. Some clinicians recommend every 3-6 months. There is no established optimal interval in humans.

What are the side effects?

Dasatinib: bleeding risk, fluid retention, pleural effusion, fatigue. Quercetin and fisetin are generally well-tolerated at senolytic doses. Intermittent dosing reduces cumulative risk.

🛒 Recommended Products

Support supplements and gear relevant to this protocol.

Affiliate links — support HighPeptides at no extra cost.

⚠️ Disclaimer

Dasatinib is a prescription oncology drug. Quercetin and fisetin are dietary supplements. The senolytic protocols described are investigational.

Not medical advice. Consult a qualified healthcare provider before starting senolytic therapy — especially if you take anticoagulants or have cardiovascular disease.